Figure 1.
AML risk classification according to the proposed integrated clinical, cytogenetic, and molecular risk stratification. *Fourteen cases without cytogenetic data were stratified as high risk due to a high white blood cell count (n = 11) or FLT3-ITD mutation (n = 3). §Cases without risk classification had an absence of metaphases for analysis and a white blood cell count <50 × 109/L, and transcripts of RUNX1-RUNX1T1 or CBFB-MYH11 were not detectable by molecular biology approaches. NPM1 mutation with FLT3-ITD wild type was found in 3 patients, and cooccurrence of NPM1 and FLT3-ITD mutations were found in 2 patients.
